Importance of recombinant human thyrotropin as an adjuvant in the radioiodine treatment of thyroid cancer

References

• Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501–511.
   PubMed Web of Science ®Google Scholar
• Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140:317–322.
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.
   PubMed Web of Science ®Google Scholar
• Edmonds CJ, Hayes S, Kermode JC, et al. Measurement of serum TSH and thyroid hormones in the management and treatment of thyroid carcinoma with radioiodine. Br J Radiol. 1977;50:799–807.
   PubMed Web of Science ®Google Scholar
• Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2002;87:4063–4068.
   PubMed Web of Science ®Google Scholar
• Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med. 2002;43:1482–1488.
   PubMed Web of Science ®Google Scholar
• Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926–932.
   PubMed Web of Science ®Google Scholar
• Barbaro D, Simi U, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab. 2003;88(9):4110–4115.
   PubMed Web of Science ®Google Scholar
• Chianelli M, Todino V, Graziano FM, et al. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol. 2009;160(3):431–436.
   PubMed Web of Science ®Google Scholar
• Lee J, Yun MJ, Nam KH, et al. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid. 2010;20(2):173–179.
   PubMed Web of Science ®Google Scholar
• Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674–1685.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. Tumeurs de la Thyroïde Refractaires Network for the Essai Stimulation Ablation Equivalence Trial. N Engl J Med. 2012;366(18):1663–1673.
   PubMed Web of Science ®Google Scholar
• Pitoia F, Marlowe RJ, Abelleira E, et al. Radioiodine thyroid remnant ablation after recombinant human thyrotropin or thyroid hormone withdrawal in patients with high-risk differentiated thyroid cancer. J Thyroid Res. 2012;2012:481568.
   PubMedGoogle Scholar
• Rosario PW, Xavier AC, Calsolari MR. Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients. Thyroid. 2010 Nov;20(11):1247–1252.
   PubMed Web of Science ®Google Scholar
• Tuttle RM, Lopez N, Leboeuf R, et al. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid. 2010 Mar;20(3):257–263.
   PubMed Web of Science ®Google Scholar
• Tala H, Robbins R, Fagin JA, et al. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab. 2011 Jul;96(7):2105–2111.
   PubMed Web of Science ®Google Scholar
• Hugo J, Robenshtok E, Grewal R, et al. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid. 2012 Oct;22(10):1007–1015.
   PubMed Web of Science ®Google Scholar
• Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid. 2012 Mar;22(3):310–317.
   PubMed Web of Science ®Google Scholar
• Bartenstein P, Calabuig EC, Maini CL, et al. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. Thyroid. 2014 Mar;24(3):480–487.
   PubMed Web of Science ®Google Scholar
• Molinaro E, Giani C, Agate L, et al. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. J Clin Endocrinol Metab. 2013;98(7):2693–2700.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–242.
   PubMed Web of Science ®Google Scholar
• Duntas LH, Biondi B. Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. Eur J Endocrinol. 2007 Jan;156(1):13–19.
   PubMed Web of Science ®Google Scholar
• Hänscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47:648–654.
   PubMed Web of Science ®Google Scholar
• Remy H, Borget I, Leboulleux S, et al. 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med. 2008;49:1445–1450.
   PubMed Web of Science ®Google Scholar
• Tal̈Eb D, Jacob T, Zotian E. Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases. Thyroid. 2004;14:465–467.
   PubMed Web of Science ®Google Scholar
• Driedger AA, Kotowycz N. Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin. Jcem. 2004;89:585–590.
   PubMed Web of Science ®Google Scholar
• Potzi C, Moameni A, Karanikas G, et al. Comparison of iodine uptake in tumour and non tumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf). 2006;65:519–523.
   PubMed Web of Science ®Google Scholar
• Ringel MD, Ladenson PW. Diagnostic accuracy of 13Il scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. Jcem. 1996;81:1724–1725.
   PubMed Web of Science ®Google Scholar
• Schneider C, Dietlein M, Eschner W, et al. Recombinant human TSH increases uptake and effective half-life of radioiodine in thyroid hormone secreting metastases of follicular thyroid cancer. Exp Clin Endocrinol Diabetes. 2012;120:160–163.
   PubMed Web of Science ®Google Scholar
• Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, et al. Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer. Endocr Pract. 2013 Jan-Feb;19(1):139–148.
   PubMed Web of Science ®Google Scholar
• Vargas GE, Uy H, Bazan C, et al. Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. JCEM. 1999;84:3867–3871.
   PubMed Web of Science ®Google Scholar
• Robbins RJ, Voelker E, Wang W, et al. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of the literature. Endocr Pract. 2000;6:460–464.
   PubMedGoogle Scholar
• Martini G, Gennari L, De Paola V, et al. The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. Thyroid. 2008 Apr;18(4):455–460.
   PubMed Web of Science ®Google Scholar
• Ippolito S, Ippolito R, Peirce C, et al. Recombinant human thyrotropin improves endothelial coronary flow reserve in thyroidectomized patients with differentiated thyroid cancer. Thyroid. 2016 Nov;26(11):1528–1534.
   PubMed Web of Science ®Google Scholar